Delivering confidence to appropriately identify urothelial carcinoma (UC) patients most likely to benefit from TECENTRIQ™ (atezolizumab)
- FDA approved to predict UC patient response to TECENTRIQ™
- Evaluate PD-L1 status with immune cell interpretation and scoring
- Designed to enhance visual contrast of immune cell staining within the tumor microenvironment